Here's Why You Should Invest in SpringWorks (SWTX) Stock Now [Yahoo! Finance]
SpringWorks Therapeutics, Inc. - common stock (SWTX)
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Following the FDA nod, not only Ogsiveo became the first approved product in the company's portfolio but it also became the first approved drug for treating desmoid tumors, a rare, aggressive tumor of the soft tissues. Ogsiveo has witnessed a strong initial uptake so far. The company's efforts to expand the drug's label also look encouraging. Let's dig deeper. Reasons to Invest in SpringWorks Stock Good Rank and Rising Estimates: SpringWorks currently has a Zacks Rank #2 (Buy). In the past 30 days, the Zacks Consensus Estimate for SpringWorks' 2024 loss per share has narrowed from $4.62 to $3.34. The same for 2025 has narrowed from $3.24 to $1.87. Shares of SpringWorks have rallied 11.3% so far this year compared with the industry's rise of 1.6%. Image Source: Zacks Investment Research Ogsiveo Becomes a Source of Revenues: Ogsiveo's net product revenues were $61.2 million in the first half of 2024. The drug has witnessed a rapid uptake so far, which is driven by strong co
Show less
Read more
Impact Snapshot
Event Time:
SWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SWTX alerts
High impacting SpringWorks Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
SWTX
News
- Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official' offer soon [Yahoo! Finance]Yahoo! Finance
- Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics [Yahoo! Finance]Yahoo! Finance
- InnovationRx: Federal Judges Halt Trump’s Cuts To NIH Research Payments [Forbes]Forbes
- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at Evercore ISI from $60.00 to $65.00. They now have an "outperform" rating on the stock.MarketBeat
- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.MarketBeat
SWTX
Earnings
- 11/12/24 - Beat
SWTX
Sec Filings
- 2/14/25 - Form 4
- 2/14/25 - Form 144
- 2/14/25 - Form SCHEDULE
- SWTX's page on the SEC website